Literature DB >> 174814

Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues.

A L Singer, R P Sherwin, A S Dunn, M M Appleman.   

Abstract

Cyclic nucleotide phosphodiesterase activity was studied in 33 malignant neoplastic, 2 benign neoplastic, and 18 nonneoplastic human mammary tissues. Enzyme activity, using both cyclic adenosine 3':5'-monophosphate and cyclic guanosine 3':5'-monosphosphate as substrates, was measured in whole homogenates over a concentration range of 1 to 100 muM. Specific activity was calculated at substrate concentrations of 1 muM (low KM enzyme activity) and 100 muM (high KM activity). Diethylaminoethyl cellulose chromatography was used to separate the different enzyme species. The malignant neoplastic tissues had higher levels of both low-KM cyclic adenosine 3':5'-monophosphate and low-KM cyclic guanosine 3':5'-monophosphate phosphodiesterases. Further, the mean value of the ratio of low-km cyclic adenosine 3':5'-monophosphate to low-KM cyclic guanosine 3':5'-monophosphate activity was higher for the cancer tissues than for the nonneoplastic tissues. Diethylaminoethyl cellulose chromatography indicated the presence of three enzymes in both neoplastic and nonneoplastic mammary tissue. The kinetic as well as regulatory properties of the separated enzymes indicated that they are distinct enzyme activities. The phosphodiesterase properties were similar for neoplastic and nonneoplastic tissues and resembled those described previously in many other mammalian tissues. While both neoplastic and nonneoplastic tissues had detectable levels of the protein activator for phosphodiesterase, the cancer tissues appeared to have a higher level.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 174814

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Structural basis for Ca2+-induced activation and dimerization of estrogen receptor α by calmodulin.

Authors:  Yonghong Zhang; Zhigang Li; David B Sacks; James B Ames
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

2.  Novel protein inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase from glioblastoma multiforme.

Authors:  S Lal; R V Raju; R K Sharma
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

3.  Experimental intraocular malignancy: the effect of intracameral perfusion.

Authors:  V G Wong; W R Green; Y P Liu; E R Marsden
Journal:  Trans Am Ophthalmol Soc       Date:  1979

4.  Cyclic nucleotide levels in human breast cancer and in rat mammary tissues during tumor development.

Authors:  E Israeli; B Raz; H Kerner; D Barzilai
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 5.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

Review 6.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

7.  Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13.

Authors:  J W Wei; R A Hickie; D J Klaassen
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Calmodulin content of rat mammary tissue and isolated cells during pregnancy and lactation.

Authors:  T L Riss; P J Bechtel; C R Baumrucker
Journal:  Biochem J       Date:  1984-05-01       Impact factor: 3.857

9.  A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

Authors:  C L O'Bryant; C H Lieu; S Leong; R Boinpally; M Basche; L Gore; K Leonardi; M K Schultz; S Hariharan; L Chow; S Diab; A Gibbs; S G Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

10.  Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells.

Authors:  Eugenia Cifuentes; Jennifer M Mataraza; Barbara A Yoshida; Mani Menon; David B Sacks; Evelyn R Barrack; G Prem-Veer Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.